{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:04:57Z","timestamp":1778043897815,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00405-025-09559-7","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:11:15Z","timestamp":1753859475000},"page":"6057-6068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["An overview of switching biological therapies for chronic rhinosinusitis with nasal polyposis (CRSwNP)"],"prefix":"10.1007","volume":"282","author":[{"given":"Talal","family":"Alharbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawaf","family":"Alsubaie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-0255","authenticated-orcid":false,"given":"Ahmad","family":"Alroqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"9559_CR1","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/jaa.s290424","volume":"14","author":"C Bachert","year":"2021","unstructured":"Bachert C, Bhattacharyya N, Desrosiers M, Khan AH (2021) Burden of disease in chronic rhinosinusitis with nasal polyps. JAA 14:127\u2013134. https:\/\/doi.org\/10.2147\/jaa.s290424","journal-title":"JAA"},{"key":"9559_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1939-4551-7-25","volume":"7","author":"C Bachert","year":"2014","unstructured":"Bachert C et al (2014) ICON: chronic rhinosinusitis. World Allergy Organ J 7:25. https:\/\/doi.org\/10.1186\/1939-4551-7-25","journal-title":"World Allergy Organ J"},{"issue":"6","key":"9559_CR3","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.jaci.2013.02.036","volume":"131","author":"CA Akdis","year":"2013","unstructured":"Akdis CA et al (2013) Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European academy of allergy and clinical immunology and the American academy of allergy, asthma & immunology. J Allergy Clin Immunol 131(6):1479\u20131490. https:\/\/doi.org\/10.1016\/j.jaci.2013.02.036","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"9559_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/moo.0000000000000594","volume":"28","author":"MS Nasta","year":"2020","unstructured":"Nasta MS, Chatzinakis VA, Georgalas CC (2020) Updates on current evidence for biologics in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 28(1):18\u201324. https:\/\/doi.org\/10.1097\/moo.0000000000000594","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"6","key":"9559_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.2500\/aap.2021.42.210080","volume":"42","author":"DV Wallace","year":"2021","unstructured":"Wallace DV (2021) Treatment options for chronic rhinosinusitis with nasal polyps. Allergy Asthma Proc 42(6):450\u2013460. https:\/\/doi.org\/10.2500\/aap.2021.42.210080","journal-title":"Allergy Asthma Proc"},{"issue":"11","key":"9559_CR6","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.3390\/life13112165","volume":"13","author":"R Cergan","year":"2023","unstructured":"Cergan R, Berghi ON, Dumitru M, Vrinceanu D, Manole F, Serboiu CS (2023) Biologics for Chronic Rhinosinusitis\u2014A Modern Option for Therapy. Life 13(11):2165. https:\/\/doi.org\/10.3390\/life13112165","journal-title":"Life"},{"issue":"6","key":"9559_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.anorl.2023.10.008","volume":"140","author":"M Fieux","year":"2023","unstructured":"Fieux M, Rumeau C, De Bonnecaze G, Papon JF, Mortuaire G (2023) Surgery for chronic rhinosinusitis with nasal polyps: an update. Eur Ann Otorhinolaryngol Head Neck Dis 140(6):297\u2013304. https:\/\/doi.org\/10.1016\/j.anorl.2023.10.008","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"issue":"6","key":"9559_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40629-022-00220-x","volume":"31","author":"L Klimek","year":"2022","unstructured":"Klimek L et al (2022) Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP). Allergo J Int 31(6):149\u2013160. https:\/\/doi.org\/10.1007\/s40629-022-00220-x","journal-title":"Allergo J Int"},{"issue":"10","key":"9559_CR9","doi-asserted-by":"publisher","first-page":"5523","DOI":"10.3390\/ijms23105523","volume":"23","author":"J Tai","year":"2022","unstructured":"Tai J, Han M, Kim TH (2022) Therapeutic strategies of biologics in chronic rhinosinusitis: current options and future targets. Int J Mol Sci 23(10):5523. https:\/\/doi.org\/10.3390\/ijms23105523","journal-title":"Int J Mol Sci"},{"issue":"2","key":"9559_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","volume":"151","author":"MA Rank","year":"2023","unstructured":"Rank MA et al (2023) The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 151(2):386\u2013398. https:\/\/doi.org\/10.1016\/j.jaci.2022.10.026","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"9559_CR11","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME et al (2022) Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 10(10):2695\u20132709. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"9559_CR12","doi-asserted-by":"publisher","first-page":"9563","DOI":"10.3390\/ijms24119563","volume":"24","author":"G Scioscia","year":"2023","unstructured":"Scioscia G et al (2023) Switching biological therapies in severe asthma. Int J Mol Sci 24(11):9563. https:\/\/doi.org\/10.3390\/ijms24119563","journal-title":"Int J Mol Sci"},{"issue":"8","key":"9559_CR13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","volume":"19","author":"J Otten","year":"2023","unstructured":"Otten J et al (2023) Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making. Expert Rev Clin Immunol 19(8):1041\u20131049. https:\/\/doi.org\/10.1080\/1744666X.2023.2218617","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"9559_CR14","doi-asserted-by":"publisher","first-page":"pp194","DOI":"10.4193\/Rhin22.489","volume":"61","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ et al (2023) EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology 61(3):pp194\u2013202. https:\/\/doi.org\/10.4193\/Rhin22.489","journal-title":"Rhinology"},{"issue":"10","key":"9559_CR15","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley M (2017) Dupilumab: First Global Approval. Drugs 77(10):1115\u20131121. https:\/\/doi.org\/10.1007\/s40265-017-0768-3","journal-title":"Drugs"},{"issue":"10209","key":"9559_CR16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"key":"9559_CR17","unstructured":"DUPIXENT\u00ae (dupilumab) in Adults with Nasal Polyps. Accessed: Apr. 01, 2025. [Online]. Available: https:\/\/www.dupixent.com\/crswnp\/"},{"issue":"5","key":"9559_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","volume":"315","author":"C Bachert","year":"2016","unstructured":"Bachert C et al (2016) Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. JAMA 315(5):469\u2013479. https:\/\/doi.org\/10.1001\/jama.2015.19330","journal-title":"JAMA"},{"issue":"1","key":"9559_CR19","doi-asserted-by":"publisher","first-page":"e1433","DOI":"10.1002\/cti2.1433","volume":"12","author":"P Gevaert","year":"2023","unstructured":"Gevaert P et al (2023) Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps. Clin Transl Immunol 12(1):e1433. https:\/\/doi.org\/10.1002\/cti2.1433","journal-title":"Clin Transl Immunol"},{"key":"9559_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2147\/JAA.S355391","volume":"15","author":"C Bachert","year":"2022","unstructured":"Bachert C et al (2022) Rapid and continuing improvements in nasal symptoms with dupilumab in patients with severe CRSwNP. J Asthma Allergy 15:557\u2013563. https:\/\/doi.org\/10.2147\/JAA.S355391","journal-title":"J Asthma Allergy"},{"issue":"10","key":"9559_CR21","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1111\/all.15772","volume":"78","author":"E De Corso","year":"2023","unstructured":"De Corso E et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL). Allergy 78(10):2669\u20132683. https:\/\/doi.org\/10.1111\/all.15772","journal-title":"Allergy"},{"issue":"5","key":"9559_CR22","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.waojou.2023.100780","volume":"16","author":"T Albrecht","year":"2023","unstructured":"Albrecht T, Sailer MM, Capitani F, van Schaik C, L\u00f6wenheim H, Becker S (2023) Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy. World Allergy Organ J 16(5):100780. https:\/\/doi.org\/10.1016\/j.waojou.2023.100780","journal-title":"World Allergy Organ J"},{"issue":"1","key":"9559_CR23","doi-asserted-by":"publisher","first-page":"104106","DOI":"10.1016\/j.amjoto.2023.104106","volume":"45","author":"C Galletti","year":"2024","unstructured":"Galletti C et al (2024) Dupilumab in chronic rhinosinusitis with nasal polyps: real life data in a multicentric Sicilian experience. Am J Otolaryngol 45(1):104106. https:\/\/doi.org\/10.1016\/j.amjoto.2023.104106","journal-title":"Am J Otolaryngol"},{"issue":"10","key":"9559_CR24","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","volume":"78","author":"RJL van der Lans","year":"2023","unstructured":"van der Lans RJL et al (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy 78(10):2684\u20132697. https:\/\/doi.org\/10.1111\/all.15796","journal-title":"Allergy"},{"issue":"12","key":"9559_CR25","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1111\/all.15507","volume":"77","author":"X Xu","year":"2022","unstructured":"Xu X, Reitsma S, Wang DY, Fokkens WJ (2022) Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease. Allergy 77(12):3593\u20133605. https:\/\/doi.org\/10.1111\/all.15507","journal-title":"Allergy"},{"issue":"9","key":"9559_CR26","doi-asserted-by":"publisher","first-page":"e047344","DOI":"10.1136\/bmjopen-2020-047344","volume":"11","author":"Q Wu","year":"2021","unstructured":"Wu Q et al (2021) Efficacy and safety of Omalizumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 11(9):e047344. https:\/\/doi.org\/10.1136\/bmjopen-2020-047344","journal-title":"BMJ Open"},{"key":"9559_CR27","unstructured":"Dosing| XOLAIR\u00ae (omalizumab). xolair. Accessed: Apr. 01, 2025. [Online]. Available: https:\/\/www.xolairhcp.com\/crswnp\/dosing-and-administration\/dosing.html"},{"issue":"3","key":"9559_CR28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","volume":"149","author":"P Gevaert","year":"2022","unstructured":"Gevaert P et al (2022) Long-term efficacy and safety of Omalizumab for nasal polyposis in an open-label extension study. J Allergy Clin Immunol 149(3):957\u2013965. https:\/\/doi.org\/10.1016\/j.jaci.2021.07.045","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"9559_CR29","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4193\/Rhino09.144","volume":"48","author":"JM Pinto","year":"2010","unstructured":"Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318\u2013324. https:\/\/doi.org\/10.4193\/Rhino09.144","journal-title":"Rhinology"},{"issue":"3","key":"9559_CR30","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P et al (2020) Efficacy and safety of Omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"9559_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","volume":"131","author":"P Gevaert","year":"2013","unstructured":"Gevaert P et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110\u2013116. https:\/\/doi.org\/10.1016\/j.jaci.2012.07.047","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"9559_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.anai.2023.11.001","volume":"132","author":"P Gevaert","year":"2024","unstructured":"Gevaert P et al (2024) Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status. Ann Allergy Asthma Immunol 132(3):355\u2013362. https:\/\/doi.org\/10.1016\/j.anai.2023.11.001","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"9559_CR33","doi-asserted-by":"publisher","first-page":"100670","DOI":"10.1016\/j.waojou.2022.100670","volume":"15","author":"TS Tat","year":"2022","unstructured":"Tat TS (2022) Omalizumab is effective in nasal polyposis with or without asthma, a real-life study. World Allergy Organ J 15(8):100670. https:\/\/doi.org\/10.1016\/j.waojou.2022.100670","journal-title":"World Allergy Organ J"},{"issue":"1","key":"9559_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/jpm14010003","volume":"14","author":"N Lombardo","year":"2023","unstructured":"Lombardo N et al (2023) Real-Life effects of Omalizumab on chronic rhinosinusitis with nasal polyposis. J Pers Med 14(1):3. https:\/\/doi.org\/10.3390\/jpm14010003","journal-title":"J Pers Med"},{"issue":"10","key":"9559_CR35","doi-asserted-by":"publisher","first-page":"100702","DOI":"10.1016\/j.waojou.2022.100702","volume":"15","author":"M Zheng","year":"2022","unstructured":"Zheng M et al (2022) Clinical effectiveness and potential predictability of Omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers - A real-life prospective study. World Allergy Organ J 15(10):100702. https:\/\/doi.org\/10.1016\/j.waojou.2022.100702","journal-title":"World Allergy Organ J"},{"issue":"6","key":"9559_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4193\/Rhin22.129","volume":"60","author":"BR Haxel","year":"2022","unstructured":"Haxel BR et al (2022) Real-world-effectiveness of biological treatment for severe chronic rhinosinusitis with nasal polyps. Rhinology 60(6):435\u2013443. https:\/\/doi.org\/10.4193\/Rhin22.129","journal-title":"Rhinology"},{"issue":"4","key":"9559_CR37","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","volume":"140","author":"C Bachert","year":"2017","unstructured":"Bachert C et al (2017) Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol 140(4):1024\u20131031. https:\/\/doi.org\/10.1016\/j.jaci.2017.05.044..e14","journal-title":"J Allergy Clin Immunol"},{"key":"9559_CR38","unstructured":"NUCALA (mepolizumab) for Healthcare Professionals. Accessed: Apr. 01, 2025. [Online]. Available: https:\/\/nucalahcp.com\/nasal-polyps\/"},{"issue":"5","key":"9559_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","volume":"128","author":"P Gevaert","year":"2011","unstructured":"Gevaert P et al (2011) Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol 128(5):989\u2013995.e1\u20138. https:\/\/doi.org\/10.1016\/j.jaci.2011.07.056","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"9559_CR40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(10):1141\u20131153. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7","journal-title":"Lancet Respir Med"},{"issue":"5","key":"9559_CR41","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert C et al (2022) Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol 149(5):1711\u20131721. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.040..e6","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"9559_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4193\/Rhin22.200","volume":"61","author":"C Hopkins","year":"2023","unstructured":"Hopkins C et al (2023) Evaluating treatment response to mepolizumab in patients with severe CRSwNP. Rhinology 61(2):108\u2013117. https:\/\/doi.org\/10.4193\/Rhin22.200","journal-title":"Rhinology"},{"issue":"3","key":"9559_CR43","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/all.15434","volume":"78","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ et al (2023) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis. Allergy 78(3):812\u2013821. https:\/\/doi.org\/10.1111\/all.15434","journal-title":"Allergy"},{"issue":"2","key":"9559_CR44","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/biomedicines11020485","volume":"11","author":"MS Dom\u00ednguez-Sosa","year":"2023","unstructured":"Dom\u00ednguez-Sosa MS et al (2023) Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps. Biomedicines 11(2):485. https:\/\/doi.org\/10.3390\/biomedicines11020485","journal-title":"Biomedicines"},{"issue":"8","key":"9559_CR45","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/jpm12081304","volume":"12","author":"S Gallo","year":"2022","unstructured":"Gallo S et al (2022) Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: A multicentric Real-Life study. J Pers Med 12(8):1304. https:\/\/doi.org\/10.3390\/jpm12081304","journal-title":"J Pers Med"},{"key":"9559_CR46","doi-asserted-by":"publisher","first-page":"175346662110093","DOI":"10.1177\/17534666211009398","volume":"15","author":"A Detoraki","year":"2021","unstructured":"Detoraki A et al (2021) Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Ther Adv Respir Dis 15:17534666211009398. https:\/\/doi.org\/10.1177\/17534666211009398","journal-title":"Ther Adv Respir Dis"},{"key":"9559_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40629-022-00220-x","volume":"31","author":"L Klimek","year":"2022","unstructured":"Klimek L et al (2022) Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP). Allergo J Int 31:1\u201312. https:\/\/doi.org\/10.1007\/s40629-022-00220-x","journal-title":"Allergo J Int"},{"issue":"4","key":"9559_CR48","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4193\/Rhin22.408","volume":"61","author":"FF Brkic","year":"2023","unstructured":"Brkic FF et al (2023) Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD. Rhinology 61(4):320\u2013327. https:\/\/doi.org\/10.4193\/Rhin22.408","journal-title":"Rhinology"},{"issue":"6","key":"9559_CR49","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s00405-024-08461-y","volume":"281","author":"C Rosso","year":"2024","unstructured":"Rosso C et al (2024) Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP. Eur Arch Otorhinolaryngol 281(6):3017\u20133023. https:\/\/doi.org\/10.1007\/s00405-024-08461-y","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"7","key":"9559_CR50","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1002\/lary.31305","volume":"134","author":"M Dorling","year":"2024","unstructured":"Dorling M, Hernaiz-Leonardo JC, Pascual A, Janjua A, Thamboo A, Javer A (2024) Real-World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps. Laryngoscope 134(7):3054\u20133059. https:\/\/doi.org\/10.1002\/lary.31305","journal-title":"Laryngoscope"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09559-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-025-09559-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-025-09559-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:57:39Z","timestamp":1764961059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-025-09559-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9559"],"URL":"https:\/\/doi.org\/10.1007\/s00405-025-09559-7","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ahmad Alroqi has served as an external expert for GSK on the CRSwNP biologic therapy advisory board and as a scientific expert (individual) for Sanofi. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}